AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15702045
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose amoxicillin (90 mg/kg/d, in 2 divided doses for 10 days)
Trial: 21815708
Drug: Pravastatin (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (10-20 mg/day)
Trial: 11999665
Drug: Conventional lipid-lowering
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional lipid-lowering drugs (fibrates, nicotinic acid, probucol)
Trial: 10458219
Drug: MA 160
RxNorm normalized name: Zhi ma oil
DrugBank: Sesame oil (DB11172)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MA 160 mg/d (one tablet per day)
Trial: 10458219
Drug: MA 800
RxNorm normalized name: Zhi ma oil
DrugBank: Sesame oil (DB11172)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MA 800 mg/d (five tablets per day)
Trial: 10458219
Drug: MA 1,600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MA 1,600 mg/d (10 tablets per day)
Trial: 350254
Drug: Various existing
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various existing methods of allocation to treatment groups
Trial: 27473843
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg for 12 months
Trial: 18585908
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy with standardized allergen extract (H‐Al per os) for one year.
Trial: 18585908
Drug: Supralingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supralingual immunotherapy with standardized allergen extract (H‐Al per os) for one year.
Trial: 18585908
Drug: Sublingual active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual active group
Trial: 16988729
Drug: Continuous renal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous renal replacement therapy (CRRT) at a dose of 35-45 ml/kg/h
Trial: 11032586
Drug: Tamoxifen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (20 to 30 mg/d for >/= 2 years)
Trial: 8252955
Drug: Oxitropium bromide
RxNorm normalized name: oxitropium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxitropium bromide (0.2 mg)
Trial: 8252955
Drug: Combined oxitropium
RxNorm normalized name: oxitropium
DrugBank: Oxitropium (DB12086)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oxitropium and fenoterol (0.2 mg and 0.4 mg)
Trial: 28641369
Drug: Soluble intercellular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble intercellular adhesion molecule‐1 (quintile 5 vs. quintile 1)
Trial: 15602800
Drug: Fluindione 20
RxNorm normalized name: fluindione 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluindione 20 mg
Trial: 1848268
Drug: Itraconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (200 mg orally twice daily)
Trial: 1848268
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B (0.6 mg/kg daily or 0.3 mg/kg in combination with flucytosine)
Trial: 6676676
Drug: Carbamazepine 100
RxNorm normalized name: carbamazepine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine 100 mg/day for 8 days
Trial: 25083241
Drug: Night-time dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Night-time dosing of thiazide diuretics
Trial: 25083241
Drug: Morning dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning dosing of thiazide diuretics
Trial: 11873000
Drug: Ritonavir (RTV)
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir (RTV) 400 mg and Saquinavir soft-gel (SQVsgc) 400 mg twice daily with Pravastatin 40 mg daily (arm 1)
Trial: 11873000
Drug: Ritonavir (RTV)
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir (RTV) 400 mg and Saquinavir soft-gel (SQVsgc) 400 mg twice daily with Simvastatin 40 mg daily (arm 2)
Trial: 11873000
Drug: Ritonavir (RTV)
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir (RTV) 400 mg and Saquinavir soft-gel (SQVsgc) 400 mg twice daily with Atorvastatin 40 mg daily (arm 3)
Trial: 11873000
Drug: Nelfinavir (NFV)
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nelfinavir (NFV) 1250 mg twice daily with Pravastatin 40 mg daily (arm 4)
Trial: 31254522
Drug: Placebo (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (20 mL saline)
Trial: 25631970
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of ferrous sulfate twice a week for 16 weeks
Trial: 19782353
Drug: Single preovulatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single preovulatory intrauterine insemination (IUI) performed 24 hours after hCG administration
Trial: 19782353
Drug: Two IUIs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two IUIs performed 12 and 36 hours after hCG administration
Trial: 19782353
Drug: Single periovulatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single periovulatory IUI performed 36 hours after hCG administration
Trial: 18585494
Drug: Full prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full prescription drug coverage (no copays, coinsurance, or deductibles) for statins, beta-blockers, ACE inhibitors, and angiotensin II receptor blockers.
Trial: 18585494
Drug: Full prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full prescription drug coverage (no copays, coinsurance, or deductibles).
Trial: 2884879
Drug: SMS 201-995
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMS 201-995 (25 micrograms, subcutaneously, twice daily)
Trial: 25194408
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplementation (250 mg, three times per week for 8 weeks)
Trial: 1772457
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection (saline)
Trial: 18082217
Drug: Prostataplex soft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostataplex soft gels (2 soft gels daily for 12 weeks)
Trial: 18082217
Drug: Placebo soft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo soft gels (2 soft gels daily for 12 weeks)
Trial: 11037850
Drug: Oral cloxacillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cloxacillin and cefixime
Trial: 8610379
Drug: BT563 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BT563 (10 mg/day for 12 days)
Trial: 8610379
Drug: ATG (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATG (5 mg/kg/day for 7 days)
Trial: 8240460
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 2 mg E2
Trial: 8240460
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 4 mg E2
Trial: 8240460
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 8 mg E2
Trial: 8240460
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 0.3 mg E2
Trial: 8240460
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of E2 (overall)
Trial: 3486756
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose (SD) of 2 mg/kg intravenously
Trial: 3486756
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose (SD) of 2 mg/kg plus a 2 mg/kg/h intravenous infusion (SDI)
Trial: 24434128
Drug: Pulsatile Electrostatic
RxNorm normalized name: PULSATILLA PRATENSIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsatile Electrostatic Field (PESF) treatment in group C (T2DM with leg ulcers)
Trial: 24434128
Drug: Pulsatile Electrostatic
RxNorm normalized name: PULSATILLA PRATENSIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsatile Electrostatic Field (PESF) treatment in group A (obese without glucose intolerance)
Trial: 24434128
Drug: Pulsatile Electrostatic
RxNorm normalized name: PULSATILLA PRATENSIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsatile Electrostatic Field (PESF) treatment in group B (obese intolerant to glucose)
Trial: 8636011
Drug: Paclitaxel 240
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 240 mg/m2
Trial: 8636011
Drug: Paclitaxel 270
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 270 mg/m2
Trial: 8636011
Drug: Paclitaxel 3-h
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 3-h infusion
Trial: 381955
Drug: Ticrynafen, 125‐‐250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticrynafen, 125‐‐250 mg/day
Trial: 381955
Drug: Probenecid, 0.5‐‐1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probenecid, 0.5‐‐1.0 g/day
Trial: 25033745
Drug: Warmed irrigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warmed irrigation solutions (37 °C) in group W
Trial: 25033745
Drug: Room temperature
RxNorm normalized name: ROOM DEODORIZER POWDER MENTOR #3202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Room temperature irrigation solutions (21 °C) in group R
Trial: 21964530
Drug: COX-2 or
RxNorm normalized name: Inova 8-2 Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COX-2 or 5-LOX inhibitors plus chemotherapy
Trial: 8655160
Drug: Azithromycin Regimen
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin Regimen A - 1.0 g once weekly for 4 weeks
Trial: 8655160
Drug: Azithromycin Regimen
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin Regimen B - 500 mg daily for 7 days
Trial: 1513195
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion (mean total dose 6.4 +/- 2.7 mg/kg)
Trial: 18476293
Drug: Drug Conservation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug Conservation (DC)
Trial: 16571140
Drug: Recombinant Hepatitis
RxNorm normalized name: Recombinant hepatitis B human immunoglobulin
DrugBank: Lenvervimab (DB17814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant Hepatitis B virus vaccine (40 microg for HIV positive patients, 20 microg for controls)
Trial: 8624183
Drug: 8 mg/d
RxNorm normalized name: Neupro 8 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg/d of buprenorphine
Trial: 8624183
Drug: 30 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/d of methadone
Trial: 8624183
Drug: 80 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/d of methadone
Trial: 8624183
Drug: low-dose methadone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: low-dose methadone
Trial: 8624183
Drug: high-dose methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high-dose methadone
Trial: 2578493
Drug: Oral hydroxyzine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hydroxyzine, 25 mg four times a day
Trial: 29663828
Drug: Nurse-led palliative
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-led palliative care intervention integrated with anti-retroviral therapy (ART)
Trial: 24656538
Drug: Cangrelor infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cangrelor infusion (bolus plus 2-h infusion) and ticagrelor (180 mg) at 0.5 h (n = 6) or 1.25 h (n = 6)
Trial: 24656538
Drug: Ticagrelor (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (90 mg twice daily for either 6 doses or 7 doses)
Trial: 24656538
Drug: Ticagrelor given
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor given before or during infusion of cangrelor
Trial: 24656538
Drug: Ticagrelor during
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor during infusion of cangrelor
Trial: 10817002
Drug: Unilateral spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral spinal anesthesia with 8 mg of 0.5% hyperbaric bupivacaine
Trial: 10817002
Drug: Combined sciatic-femoral
RxNorm normalized name: Sus scrofa temporal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined sciatic-femoral nerve block with 25 ml of 2% mepivacaine
Trial: 6841658
Drug: Deltoid morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deltoid morphine (8 and 16 mg)
Trial: 6841658
Drug: Deltoid methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deltoid methadone (10 mg)
Trial: 29152781
Drug: Glecaprevir and
RxNorm normalized name: glecaprevir and pibrentasvir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glecaprevir and pibrentasvir (G/P; 300 mg/120 mg) for 12 weeks
Trial: 29152781
Drug: Glecaprevir and
RxNorm normalized name: glecaprevir and pibrentasvir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glecaprevir and pibrentasvir (G/P; 300 mg/120 mg) for 16 weeks
Trial: 27819111
Drug: Loop diuretics
RxNorm normalized name: LOOP DIURETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loop diuretics (including doses ≥80 mg furosemide equivalent/day)
Trial: 27819111
Drug: No loop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No loop diuretics
Trial: 24388010
Drug: 500 index
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 index of reactivity (IR) tablets
Trial: 24388010
Drug: 300 index
RxNorm normalized name: gr pol-orc/sw ver/rye/Kent/tim 300 index of reactivity SUBLINGUAL TABLET, SUBLINGUAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 index of reactivity (IR) tablets
Trial: 22475306
Drug: Control (benzocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (benzocaine gel)
Trial: 21992993
Drug: 0.5% timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% timolol aqueous solution
Trial: 10465182
Drug: Transdermal oestradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal oestradiol 80 microg with continuous oral norethisterone 1 mg
Trial: 373393
Drug: Potassium chloride
RxNorm normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Potassium chloride (1500 mg daily)
Trial: 2565210
Drug: Amiloride (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride (5 mg daily)
Trial: 373393
Drug: Triamterene (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triamterene (75 mg daily)
Trial: 24795252
Drug: Hydrochlorothiazide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (50 mg daily)
Trial: 21861935
Drug: Hylan G-F
RxNorm normalized name: hylan G-F 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hylan G-F 20 injections (4 courses of 3 × 2.0 ml at 6 month intervals)
Trial: 21861935
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care for knee OA without injections
Trial: 19718004
Drug: Periodontal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periodontal therapy combined with tacrolimus
Trial: 24593836
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene instructions only (Control)
Trial: 17230289
Drug: 50 IU
RxNorm normalized name: Pegaspargase 750 IU/1 ML Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 IU Syntocinon (in 30 ml N saline)
Trial: 17230289
Drug: 800 mcg
RxNorm normalized name: Biotin 800 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mcg misoprostol (in 30 ml N saline)
Trial: 17230289
Drug: 30 ml
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml N saline (control)
Trial: 7821456
Drug: Oral tetracycline
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tetracycline (250 mg twice daily for 12 weeks)
Trial: 7821456
Drug: Oral tetracycline
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tetracycline (250 mg twice daily for 12 weeks) and topical prednisolone (for the first 7 days)
Trial: 7821456
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (Control group A)
Trial: 2839579
Drug: Intranasal sprays
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal sprays of recombinant beta serine interferon (rIFN‐beta ser)
Trial: 2839579
Drug: Daily nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily nasal drops of rIFN‐beta ser
Trial: 2839579
Drug: Low-dose rIFN‐beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose rIFN‐beta ser
Trial: 2839579
Drug: High-dose rIFN‐beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose rIFN‐beta ser
Trial: 18200775
Drug: Nifedipine (twice-daily)
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine (twice-daily)
Trial: 14741066
Drug: Extended-release lovastatin
RxNorm normalized name: lovastatin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release lovastatin (20 mg)
Trial: 14741066
Drug: Immediate-release lovastatin
RxNorm normalized name: lovastatin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release lovastatin (20 mg)
Trial: 11716446
Drug: Oral cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclophosphamide 50 mg/day and tamoxifen 20 mg/day plus 1‐hexylcarbamoyl‐5‐fluorouracil 300 mg/day for 2 years
Trial: 11716446
Drug: Oral cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclophosphamide 50 mg/day and tamoxifen 20 mg/day for 2 years
Trial: 26626823
Drug: Normal energy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal energy food foam (NEF1, 280 kJ/400 mL)
Trial: 26626823
Drug: Very low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low energy food foam (VLEF, 36 kJ/400 mL)
Trial: 23136318
Drug: GEL (lubricant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEL (lubricant gel use before speculum insertion)
Trial: 23136318
Drug: NO GEL
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NO GEL (no lubricant gel use before speculum insertion)
Trial: 23136318
Drug: GEL (lubricant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEL (lubricant gel use) in premenopausal women
Trial: 23136318
Drug: GEL (lubricant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEL (lubricant gel use) in postmenopausal women
Trial: 23136318
Drug: GEL (lubricant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEL (lubricant gel use) in women of reproductive age
Trial: 20032194
Drug: Vabicaserin (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vabicaserin (oral administration)
Trial: 20032194
Drug: Vabicaserin metabolism
RxNorm normalized name: Vabicaserin
DrugBank: Vabicaserin (DB12071)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vabicaserin metabolism
Trial: 15750171
Drug: Multiple-time graphical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-time graphical analysis of 18F-fluoro-L-DOPA uptake constant (K(i), min(−1)) in basal ganglia
Trial: 15750171
Drug: SPM analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPM analysis of 18F-fluoro-L-DOPA uptake constant (K(i), min(−1)) in basal ganglia
Trial: 9147856
Drug: Clodronate 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 3 x 800 mg orally
Trial: 1491771
Drug: Cyclic hormone
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic hormone replacement therapy with conjugated estrogens (0.625 mg and 1.25 mg) and progestagens (medroxyprogesterone acetate or medrogestone)
Trial: 22520669
Drug: 3-monthly GP
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 3-monthly GP visits (intensive care)
Trial: 20479407
Drug: Paclitaxel added
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel added to adjuvant doxorubicin plus cyclophosphamide (AC) chemotherapy
Trial: 20479407
Drug: AC chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC chemotherapy alone
Trial: 10926637
Drug: 7 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 g/day of pyruvate